The global point-of-care influenza diagnostics market reached approximately USD 440.47 million in 2025 and is expected to grow to USD 709.52 million by 2033, at a CAGR of 6.14% during the period from 2025 to 2033. Key growth drivers include increased prevalence and severity of seasonal and zoonotic influenza outbreaks, rapid adoption of decentralized testing, technological innovation in diagnostics, and integration with telehealth and home-based healthcare solutions.
Seasonal flu annually affects up to a billion people worldwide, with severe illness in millions and hundreds of thousands of respiratory deaths. Efficient rapid POC tests empower timely flu detection and intervention in clinics, pharmacies, urgent care, and even at home. Integration with telehealth and FDA-approved at-home tests, such as those introduced by Roche and Healgen, have enhanced early diagnosis, allowing real-time virtual consultations and symptom management. These shifts accelerate intervention, curb transmission, and increase testing reach across diverse settings.
Technological breakthroughs in both rapid antigen and molecular diagnostics have improved sensitivity, accuracy, and convenience. Examples include CLIA-waived multiplex immunoassays like QuidelOrtho’s tests that enable triple detection (e.g., flu + SARS-CoV-2) and user-friendly at-home kits. Recent FDA emergency use authorizations, rapid RT-PCR advancements, and digital health tool integration—including AI decision support—are broadening the use and acceptance of POC influenza tests. Strategic collaborations and acquisitions continue, while regulatory approval remains critical for product entry and expansion.
Rapid antigen tests (RIDTs) led the market in 2024 due to their speed, accessibility, and affordability, supporting quick clinical decisions. Technological upgrades have increased their reliability, and digital/multiplex versions are increasingly common. Molecular point-of-care tests are growing rapidly for their superior sensitivity and lab-like accuracy, now available in compact, portable formats suitable for primary and urgent care settings.
Influenza A test kits dominate the market because influenza A is the most common and rapidly evolving cause of seasonal and pandemic flu. Rapid detection is pivotal for outbreak control, while multiplex kits covering both A and B viruses see strong demand, exemplified by innovations that enable simultaneous detection of flu and COVID-19.
Immunoassay-based platforms are widely deployed thanks to their cost-effectiveness and scalable application in point-of-care, especially for seasonal surges. Ongoing improvements are making them faster and more accurate. Molecular diagnostics—known for high sensitivity—support detection of low viral loads and differentiation between flu types, supporting critical and high-throughput needs.
| Report Attribute | Details |
|---|---|
| Market Size (2025) | USD 440.47 million |
| Forecast (2033) | USD 709.52 million |
| CAGR (2025–2033) | 6.14% |
| Historical Data | 2021–2023 |
| Segments Covered | Test Type, Influenza Strain, Technology, End-Use, Region |
| Regions/Countries | U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Sweden, Denmark, Japan, China, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
| Top Companies | Abbott, BD, Danaher/Cepheid, Quidel, Qiagen, Roche, Bio-Rad, BioMerieux, Diasorin, Hologic, Thermo/Remel, Fujirebio, Visby Medical, Twist |
What is the market size for point-of-care influenza diagnostics in 2025?
The market is estimated at USD 440.47 million in 2025.
What is the projected growth rate?
The market will expand at a CAGR of 6.14% from 2025 to 2033.
Which region is the largest market?
North America led the global market in 2024 and is a key growth driver.
What is the dominant test type and technology?
Rapid antigen tests and immunoassay-based platforms are most widely used, with molecular diagnostics quickly gaining share.
Who are the leading companies in the market?
Major players include Abbott, BD, Danaher, Quidel, Qiagen, Roche, Bio-Rad, BioMerieux, Diasorin, Hologic, Thermo, Fujirebio, and Visby Medical.
